Evidence map›Paper›PMID 42618507›Full record

ArticleChemPlusChem2026

Cobalt Oxide/Nickel Cobalt Sulfide/Poly(1,8-diaminonaphthalene) Electrochemical Sensor-Based Therapeutic Monitoring of Primaquine in Urine to Combat Low Treatment Adherence in Vivax Malaria Therapy.

Faith Muthoni Wangui, Darko Kwabena Adu, John Alake, Malachie Monyele Tembo, Rajshekhar Karpoormath

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemPlusChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Faith Muthoni WanguiDepartment of Pharmaceutical Chemistry, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
Darko Kwabena AduDepartment of Pharmaceutical Chemistry, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
John AlakeDepartment of Pharmaceutical Chemistry, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
Malachie Monyele TemboDepartment of Pharmaceutical Chemistry, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.ORCID 0000-0001-6344-4707
Rajshekhar KarpoormathDepartment of Pharmaceutical Chemistry, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.ORCID 0000-0002-0114-4140

Funding

College of Health Sciences, University of KwaZulu-Natal UKZN (RM27)
6 · The paper itself

Abstract

Patients' compliance with primaquine treatment is low due to the long 14-day duration of primaquine and the toxic side effects, including acute hemolytic anemia. This study aimed to develop a cobalt oxide/nickel cobalt sulfide/poly(1,8-diaminonaphthalene) (Co

Indexed as

1-NaphthylamineAntimalarialsCobaltElectrochemical TechniquesNickelOxidesPolymersPrimaquineHumansNanocomposites1-NaphthylamineAntimalarialsCobaltcobaltous sulfidecobalt oxideNickelOxidesPolymersPrimaquinecobalt oxidemalarianickel cobalt sensorspoly(1,8‐diaminonaphthalene)primaquine

Identifiers

PMID42618507
PMCPMC13489975

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.